3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO, CA
Shareholders Approve Amendment to 2021 Equity Incentive Plan
Provides Corporate Update and Reports Financial Results for the First Quarter 2026
Annual Report to Security Holders
Provides Corporate Update and Reports Financial Results for the Year Ended 2025
Director Resignation - Mary Fisher Steps Down from Dermata Board
Dermata Therapeutics Dismisses Baker Tilly as Independent Accountant
Dermata Therapeutics Increases Common Stock Offering by $705,000
Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Q1
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Schedule 13D - Ownership Report
Amended Schedule 13G - Ownership Report
Amended Schedule 13D - Ownership Report
Submission Upload
Correspondence